Ignite Creation Date:
2024-05-06 @ 10:30 AM
Last Modification Date:
2024-10-26 @ 12:31 PM
Study NCT ID:
NCT03279770
Status:
UNKNOWN
Last Update Posted:
2017-09-15
First Post:
2017-05-11
Brief Title:
Circulating Non-coding RNAs and Cardiovascular Outcomes in Patients With Dyslipidemia and Atherosclerosis
Sponsor:
National Taiwan University Hospital
Organization:
National Taiwan University Hospital
Study Overview
Official Title:
Circulating Non-coding RNAs and Cardiovascular Outcomes in Patients With Dyslipidemia and Atherosclerosis
Status:
UNKNOWN
Status Verified Date:
2017-09
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Cardiovascular diseases and stroke are the major causes of morbidity and death in Taiwan There is a clear need to identify novel mediators of atherosclerosis in dyslipidemic patients to provide insights into the pathogenesis to tailor clinical care based on cardiovascular risks and to develop new therapeutic strategies
While the roles of lncRNAs in human diseases including cancer and neurodegenerative disorders are beginning to emerge it remains unclear how lncRNA regulation contributes to atherosclerotic vascular diseases in patients with dyslipidemia In this proposal we seek to apply next-generation sequencing technology to investigate circulating plasma and peripheral blood mononuclear cells PBMC lncRNA expression in control subjects and in dyslipidemic patients with and without atherosclerotic vascular diseases CAD ischemic stroke and PAOD The results from these experiments will lead to better understanding of how circulating lncRNAs contribute to atherosclerotic cardiovascular complications
While the roles of lncRNAs in human diseases including cancer and neurodegenerative disorders are beginning to emerge it remains unclear how lncRNA regulation contributes to atherosclerotic vascular diseases in patients with dyslipidemia In this proposal we seek to apply next-generation sequencing technology to investigate circulating plasma and peripheral blood mononuclear cells PBMC lncRNA expression in control subjects and in dyslipidemic patients with and without atherosclerotic vascular diseases CAD ischemic stroke and PAOD The results from these experiments will lead to better understanding of how circulating lncRNAs contribute to atherosclerotic cardiovascular complications
Detailed Description:
Cardiovascular diseases and stroke are the major causes of morbidity and death in Taiwan Patients with dyslipidemia are prone to atherosclerosis which predispose to various cardiovascular pathology including coronary artery disease CAD ischemic stroke and peripheral artery occlusive disease PAOD There are however no reliable biomarkers to detect atherosclerotic vascular diseases among dyslipidemic patients or to predict the risks of cardiovascular morbidities and mortality among patients with atherosclerosis There is a clear need to identify novel mediators of atherosclerosis in dyslipidemic patients to provide insights into the pathogenesis to tailor clinical care based on cardiovascular risks and to develop new therapeutic strategies
It has become increasingly clear that the transcription of the eukaryotic genome is far more pervasive and complex than previously appreciated While the expression of messenger RNAs mRNAs and microRNAs miRNAs account for only 1 of all transcribed species up to 90 of the mammalian genome is transcribed as long non-coding RNAs lncRNAs a heterogeneous group of non-coding transcripts longer than 200 nucleotides LncRNAs have been shown to be functional and involved in specific physiological and pathological processes through epigenetic transcriptional and post-transcriptional mechanisms While the roles of lncRNAs in human diseases including cancer and neurodegenerative disorders are beginning to emerge it remains unclear how lncRNA regulation contributes to atherosclerotic vascular diseases in patients with dyslipidemia
In this proposal we seek to apply next-generation sequencing technology to investigate circulating plasma and peripheral blood mononuclear cells PBMC lncRNA expression in control subjects and in dyslipidemic patients with and without atherosclerotic vascular diseases CAD ischemic stroke and PAOD We will test the hypothesis that circulating lncRNA expression signature can reflect the atherosclerotic disease states in patients with dyslipidemia A gene co-expression network analysis will be conducted to identify lncRNAs that are functionally involved in the pathogenesis of atherosclerosis With the experimental results from an initial dyslipidemic cohort we will establish an atherosclerosis scoring model on the basis of circulating lncRNA expression signature to facilitate the detection of atherosclerotic vascular diseases in patients with dyslipidemia The accuracy sensitivity and specificity of the lncRNA-based atherosclerosis scoring system will then be tested in an independent large validation cohort Next we propose to test the hypothesis that circulating lncRNAs can be novel prognostic biomarkers to predict atherosclerosis progression and cardiovascular outcomes in dyslipidemic patients The results from these experiments will lead to better understanding of how circulating lncRNAs contribute to atherosclerotic cardiovascular complications These studies will also establish a set of novel lncRNA-based diagnostic and prognostic biomarker in dyslipidemic patients to improve clinical preventive and therapeutic care In addition the findings from these studies will help to develop novel therapeutic strategies to treat or prevent atherosclerotic vascular diseases in patients with dyslipidemia
It has become increasingly clear that the transcription of the eukaryotic genome is far more pervasive and complex than previously appreciated While the expression of messenger RNAs mRNAs and microRNAs miRNAs account for only 1 of all transcribed species up to 90 of the mammalian genome is transcribed as long non-coding RNAs lncRNAs a heterogeneous group of non-coding transcripts longer than 200 nucleotides LncRNAs have been shown to be functional and involved in specific physiological and pathological processes through epigenetic transcriptional and post-transcriptional mechanisms While the roles of lncRNAs in human diseases including cancer and neurodegenerative disorders are beginning to emerge it remains unclear how lncRNA regulation contributes to atherosclerotic vascular diseases in patients with dyslipidemia
In this proposal we seek to apply next-generation sequencing technology to investigate circulating plasma and peripheral blood mononuclear cells PBMC lncRNA expression in control subjects and in dyslipidemic patients with and without atherosclerotic vascular diseases CAD ischemic stroke and PAOD We will test the hypothesis that circulating lncRNA expression signature can reflect the atherosclerotic disease states in patients with dyslipidemia A gene co-expression network analysis will be conducted to identify lncRNAs that are functionally involved in the pathogenesis of atherosclerosis With the experimental results from an initial dyslipidemic cohort we will establish an atherosclerosis scoring model on the basis of circulating lncRNA expression signature to facilitate the detection of atherosclerotic vascular diseases in patients with dyslipidemia The accuracy sensitivity and specificity of the lncRNA-based atherosclerosis scoring system will then be tested in an independent large validation cohort Next we propose to test the hypothesis that circulating lncRNAs can be novel prognostic biomarkers to predict atherosclerosis progression and cardiovascular outcomes in dyslipidemic patients The results from these experiments will lead to better understanding of how circulating lncRNAs contribute to atherosclerotic cardiovascular complications These studies will also establish a set of novel lncRNA-based diagnostic and prognostic biomarker in dyslipidemic patients to improve clinical preventive and therapeutic care In addition the findings from these studies will help to develop novel therapeutic strategies to treat or prevent atherosclerotic vascular diseases in patients with dyslipidemia
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None